In many in vitro and in vivo ischemic heart, cardiac hypertrophy and fibrosis models, the commonly used agents noradrenaline and angiotensin II increased cardiac work and oxygen demand (Figure 2 and Figure 3). This evidence concerns the gene AGT and cardiac hypertrophy.